Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 4, 2010, Pages 1576-1581

  Alain, Tommy ^a   Lun, XueQing ^b   Martineau, Yvan ^a   Sean, Polen ^a   Pulendran, Bali ^c   Petroulakis, Emmanuel ^a   Zemp, Franz J ^b   Lemay, Chantal G ^d   Roy, Dominic ^d   Bell, John C ^d   Thomas, George ^e   Kozma, Sara C ^e   Forsyth, Peter A ^b   Costa Mattioli, Mauro ^f   Sonenberg, Nahum ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c EMORY UNIVERSITY   (United States)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CINCINNATI   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Innate antiviral immunity; Malignant gliomas; mTORC1; Oncolytic viruses

Indexed keywords

INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; ONCOLYTIC VIRUS; RAPAMYCIN; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; INTERFERON PRODUCTION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RAT; TUMOR CELL DESTRUCTION; VESICULAR STOMATITIS VIRUS; VIRUS MUTANT;

ANIMALS; CELL LINE; CELL LINE, TUMOR; FEMALE; GLIOMA; INTERFERON TYPE I; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; RATS; RATS, INBRED F344; RIBOSOMAL PROTEIN S6 KINASES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIROLIMUS; TRANSCRIPTION FACTORS; VESICULAR STOMATITIS; VESICULOVIRUS;

MAMMALIA; MUS; RATTUS; VESICULAR STOMATITIS VIRUS;

EID: 76549101731     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912344107     Document Type: Article

References (39)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323-33 1.
2. Hambardzumyan D, Becher OJ, Holland EC (2008) Cancer stem cells and survival pathways. Cell Cycle 7:1371-1378.
3. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC (2009) modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2:89-95.
4. Shai R, et al. (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22:4918-4923.
5. Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206.
6. Anonymous; Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
7. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
8. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
9. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307-318.
10. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471-484.
11. Costa-Mattioli M, Sonenberg N (2008) RAPping production of type I interferon in pDCs through mTOR. Nat Immunol 9:1097-1099.
12. Cao W, et al. (2008) Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 9:1157-1164.
13. Colina R, et al. (2008) Translational control of the innate immune response through IRF-7. Nature 452:323-328.
14. Katze MG, He Y, Gale M, Jr (2002) Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675-687.
15. Meylan E, Tschopp J, Karin M (2006) Intracellular pattern recognition receptors in the host response. Nature 442:39-44.
16. Stojdl DF, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
17. Stojdl DF, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821-825.
18. Balachandran S, Barber GN (2000) Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50:135-138.
19. Obuchi M, Fernandez M, Barber GN (2003) Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 77:8843-8856.
20. Belkowski LS, Sen GC (1987) Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. J Virol 61:653-660.
21. Lun X, et al. (2006) Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 98:1546-1557.
22. Wollmann G, Robek MD, van den Pol AN (2007) Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol 81:1479-1491.
23. Lun XQ, et al. (2009) Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15:2777-2788.
24. Barth RF (1998) Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36:91-102.
25. Yang WQ, et al. (2004) Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res10:8561-8576.
26. Pende M, et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112-3124.
27. Costa-Mattioli M, Svitkin Y, Sonenberg N (2004) La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol Cell Biol 24:6861-6870.
28. Berlanga JJ, et al. (2006) Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J 25:1730-1740.
29. Baltzis D, et al. (2004) Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. J Virol 78:12747-12761.
30. Durbin RK, Mertz SE, Koromilas AE, Durbin JE (2002) PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol 15:41-51.
31. Honda K, Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:644-658.
32. Nguyên TL, et al. (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 105:14981-14986.
33. Lun XQ, et al. (2007) Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 67:8818-8827.
34. Alonso MM, et al. (2007) Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14:756-761.
35. Alonso MM, et al. (2008) Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16:487-493.
36. Stanford MM, et al. (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16:52-59.
37. Homicsko K, Lukashev A, Iggo RD (2005) RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 65:6882-6890.
38. Moriyama EH, Bisland SK, Lilge L, Wilson BC (2004) Bioluminescence imaging of the response of rat gliosarcoma to ALA-PpIX-mediated photodynamic therapy. Photochem Photobiol 80:242-249.
39. Szentirmai O, et al. (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58:365-372.